Tom van Meerten

5.9k total citations
64 papers, 1.7k citations indexed

About

Tom van Meerten is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Tom van Meerten has authored 64 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 34 papers in Pathology and Forensic Medicine and 15 papers in Immunology. Recurrent topics in Tom van Meerten's work include Lymphoma Diagnosis and Treatment (34 papers), CAR-T cell therapy research (28 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Tom van Meerten is often cited by papers focused on Lymphoma Diagnosis and Treatment (34 papers), CAR-T cell therapy research (28 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Tom van Meerten collaborates with scholars based in Netherlands, United States and Germany. Tom van Meerten's co-authors include Anton Hagenbeek, Saskia B. Ebeling, Jan G. J. van de Winkel, Paul W.H.I. Parren, Samantha Hol, Edwin Bremer, Tom Vink, Wendy J.M. Mackus, Rozemarijn S. van Rijn and Jerry W. Slootstra and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Tom van Meerten

57 papers receiving 1.6k citations

Peers

Tom van Meerten
Oliver Manzke Germany
Mariele Goebeler Germany
Matthias Klinger Germany
Johannes Duell Germany
Carol O’Hear United States
Carla J. de Boer Netherlands
Carsten Reinhardt Germany
Amitkumar Mehta United States
Weiyun Z. Ai United States
Jamie Honeychurch United Kingdom
Oliver Manzke Germany
Tom van Meerten
Citations per year, relative to Tom van Meerten Tom van Meerten (= 1×) peers Oliver Manzke

Countries citing papers authored by Tom van Meerten

Since Specialization
Citations

This map shows the geographic impact of Tom van Meerten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom van Meerten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom van Meerten more than expected).

Fields of papers citing papers by Tom van Meerten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom van Meerten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom van Meerten. The network helps show where Tom van Meerten may publish in the future.

Co-authorship network of co-authors of Tom van Meerten

This figure shows the co-authorship network connecting the top 25 collaborators of Tom van Meerten. A scholar is included among the top collaborators of Tom van Meerten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom van Meerten. Tom van Meerten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2025). Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 26(2). 200–213. 9 indexed citations
2.
Visser, Nienke, Maurien Pruis, Jan Jacob Schuringa, et al.. (2025). K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies. PubMed. 33(2). 200988–200988.
3.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2024). Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.. Journal of Clinical Oncology. 42(16_suppl). 7007–7007. 4 indexed citations
4.
Jurczak, Wojciech, Michael Wang, Marek Trněný, et al.. (2024). Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study. Clinical Lymphoma Myeloma & Leukemia. 24. S226–S226.
5.
6.
Lin, Yusheng, Ghizlane Choukrani, Valerie R. Wiersma, et al.. (2024). VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses. Experimental Hematology and Oncology. 13(1). 35–35. 8 indexed citations
7.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2023). Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Blood. 142(Supplement 2). LBA–2. 13 indexed citations
8.
Doesum, Jaap A. van, Anne M. Spanjaart, Margot Jak, et al.. (2023). Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities. Cancers. 15(22). 5443–5443. 9 indexed citations
9.
Brink, Mirian, Martine E.D. Chamuleau, Rolf E. Brouwer, et al.. (2023). R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study. American Journal of Hematology. 99(2). 216–222. 11 indexed citations
10.
Huls, Gerwin, et al.. (2022). CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma. Biomedicines. 10(5). 1175–1175. 29 indexed citations
11.
Spanjaart, Anne M., Milan Kos, Pim Mutsaers, et al.. (2022). Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities. JCO Oncology Practice. 19(3). e407–e416. 7 indexed citations
12.
Doesum, Jaap A. van, Max Beijert, Marcel Nijland, et al.. (2021). Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy. Blood. 138(Supplement 1). 2510–2510. 3 indexed citations
13.
Brink, Mirian, Joost S.P. Vermaat, Josée M. Zijlstra, et al.. (2021). Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Advances. 5(15). 2958–2964. 16 indexed citations
14.
He, Yuan, Ewa Cendrowicz, Rudolf S.N. Fehrmann, et al.. (2019). CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. Cancer Immunology Research. 7(10). 1663–1671. 28 indexed citations
15.
Topp, Max S., Tom van Meerten, Roch Houot, et al.. (2019). Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. Blood. 134(Supplement_1). 243–243. 42 indexed citations
16.
Kwee, Thomas C., Marcel Nijland, Gerwin Huls, et al.. (2018). Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 132. 27–38. 17 indexed citations
17.
Watanabe, Keisuke, Seitaro Terakura, Anton C. Martens, et al.. (2014). Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells. The Journal of Immunology. 194(3). 911–920. 223 indexed citations
18.
Meerten, Tom van & Anton Hagenbeek. (2011). Novel antibodies against follicular non-Hodgkin’s lymphoma. Best Practice & Research Clinical Haematology. 24(2). 231–256. 13 indexed citations
19.
Meerten, Tom van & Anton Hagenbeek. (2010). CD20-Targeted Therapy: The Next Generation of Antibodies. Seminars in Hematology. 47(2). 199–210. 68 indexed citations
20.
Teeling, Jessica L., Wendy J.M. Mackus, Stephen A. Beers, et al.. (2006). The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20. The Journal of Immunology. 177(1). 362–371. 466 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oliver Manzke Breakdown of academic impact, for papers by Mariele Goebeler Breakdown of academic impact, for papers by Matthias Klinger Breakdown of academic impact, for papers by Johannes Duell Breakdown of academic impact, for papers by Carol O’Hear Breakdown of academic impact, for papers by Carla J. de Boer Breakdown of academic impact, for papers by Carsten Reinhardt Breakdown of academic impact, for papers by Amitkumar Mehta Breakdown of academic impact, for papers by Weiyun Z. Ai Breakdown of academic impact, for papers by Jamie Honeychurch
Rankless by CCL
2026